Review
Health Care Sciences & Services
Sagnik Sen, Kim Ramasamy, Sobha Sivaprasad
Summary: The review evaluated the relative importance of each risk factor in visual prognostication of diabetic macular oedema (DMO) eyes post-treatment and emphasized the significance of phenotypes formed by combining these factors in predicting visual outcomes. The development of stratification based on these phenotypes for personalized medicine in DMO treatment was proposed.
JOURNAL OF PERSONALIZED MEDICINE
(2021)
Review
Ophthalmology
Matias Iglicki, David Perez Gonzalez, Anat Loewenstein, Dinah Zur
Summary: Intravitreal injections have improved the treatment of diabetic macular oedema (DMO), but real-world data shows a disparity between clinical trials and daily practice. Long-lasting drugs and devices may bridge this gap, offering more feasible treatment options to control the global epidemic of diabetic eye disease.
Review
Cell Biology
Milagros Mateos-Olivares, Luis Garcia-Onrubia, Fco. Javier Valentin-Bravo, Rogelio Gonzalez-Sarmiento, Maribel Lopez-Galvez, J. Carlos Pastor, Ricardo Usategui-Martin, Salvador Pastor-Idoate
Summary: Diabetic macular oedema (DMO) is a leading cause of vision loss associated with diabetic retinopathy (DR), and anti-VEGF therapy has become the standard treatment worldwide. However, there is no single standard therapy for all patients with DMO refractory to anti-VEGF treatment. The Rho/ROCK signaling pathway has been identified as a potential target for new treatments, and a better understanding of the role of Rho-kinase/ROCK may lead to the development of new strategies for refractory DMO treatment and prevention.
Article
Ophthalmology
Peter Alsaloum, Matthew W. Russell, Victoria Blaga, Blanche L. Kuo, Anna K. Wu, Brian J. Liu, Carolina C. S. Valentim, Colin M. Xu, Justin C. Muste, Madhukar Kumar, Rishi P. Singh
Summary: This study aimed to investigate the time to onset of disease in the fellow eye of patients with unilateral diabetic macular edema (DME) and identify risk factors for the development of bilateral DME. The results showed that most patients developed bilateral DME within the first year after initial diagnosis. Poor glycemic control and diabetic foot disease were risk factors associated with bilateral eye involvement. Therefore, clinicians may consider screening the fellow eye of high-risk individuals at each appointment within the first year of diagnosis.
Article
Multidisciplinary Sciences
Faran W. Sabeti, Bhim J. Rai, Josh van Kleef, Emilie M. F. Rohan, Corinne Carle, Richard Barry, Rohan Essex, Christopher Nolan, Ted Maddess
Summary: This study compared macular structure obtained from optical coherence tomography (OCT) with retinal function measured objectively with the ObjectiveFIELD Analyzer (OFA) and Matrix perimetry. The results showed that changes in retinal function measured by OFA may be a more effective method for monitoring diabetic macular edema (DME) over time compared to Matrix perimetry data.
Article
Ophthalmology
Jianbo Mao, Shian Zhang, Zicheng Zheng, Xinyi Deng, Chenyi Liu, Yiqi Chen, Shixin Zhao, Yun Zhang, Lijun Shen
Summary: In eyes with diabetic macular oedema (DME), levels of inflammatory cytokines in the aqueous humour (AH) varied among different DME morphologies. The number of hyper-reflective foci (HF) was associated with certain cytokine levels and predicted a significant decrease in central macular thickness (CMT) when present in multiple at baseline.
ACTA OPHTHALMOLOGICA
(2022)
Article
Ophthalmology
Cemal Ozsaygili, Bekir Kucuk, Yener Yildirim
Summary: In this retrospective cohort study of treatment-naive diabetic macular oedema patients, the efficacy of aflibercept treatment in improving central retinal thickness and best-corrected visual acuity was not affected by the presence or development of posterior vitreous detachment (PVD).
BRITISH JOURNAL OF OPHTHALMOLOGY
(2021)
Article
Ophthalmology
Yutaka Yamada, Yoshihiro Takamura, Masakazu Morioka, Makoto Gozawa, Takehiro Matsumura, Masaru Inatani
Summary: The study found that patients with residual oedema had significantly higher central retinal thickness, poorer BCVA at 1 and 3 months, and larger white area (WA) size compared to those without residual oedema at 1, 3, and 6 months. The microaneurysm (MA) density in the area with persistent oedema was significantly higher than in the area with improved oedema at 1 and 6 months. High MA density and extensive swelling may be characteristic of residual oedema following treatment for diabetic macular oedema with intravitreal injection of either aflibercept or ranibizumab.
ACTA OPHTHALMOLOGICA
(2021)
Article
Ophthalmology
Carlos D. Nunez-Amaro, Mariana Lopez, Elva Adan-Castro, Ma. Ludivina Robles-Osorio, Renata Garcia-Franco, Marlon Garcia-Roa, Yolanda Villalpando-Gomez, Paulina Ramirez-Neria, Nayeli Pineiro, Juan Fernando Rubio-Mijangos, Jorge Sanchez, Gabriela Ramirez-Hernandez, Lourdes Siqueiros-Marquez, Nundehui Diaz-Lezama, Ellery Lopez-Star, Thomas Bertsch, Gonzalo Marinez de la Escalera, Jakob Triebel, Carmen Clapp
Summary: Oral levosulpiride for 8 weeks improved visual and structural outcomes in patients with centre-involving diabetic macular oedema (DME) by mechanisms that may include intraocular upregulation of vasoinhibin and downregulation of VEGF and PlGF. Larger clinical trials evaluating long-term efficacy and safety are warranted.
Article
Ophthalmology
Ana Rita Santos, Miguel Raimundo, Dalila Alves, Marta Lopes, Sergio Pestana, Joao Figueira, Jose Cunha-Vaz, Rufino Silva
Summary: Microperimetry and mfERG were effective in demonstrating functional improvement in DMO patients after treatment with ranibizumab, with significant improvement in retinal sensitivity observed, particularly in good BCVA responders. Additionally, overall retinal sensitivity was correlated with BCVA improvement.
Article
Ophthalmology
Sanjeeb Bhandari, Vuong Nguyen, Adrian Hunt, Pierre-Henry Gabrielle, Francesco Viola, Hemal Mehta, Les Manning, David Squirrell, Jennifer Arnold, Ian L. McAllister, Daniel Barthelmes, Mark Gillies
Summary: This study aims to analyze the changes in clinical outcomes of neovascular age-related macular degeneration (nAMD), diabetic macular oedema (DMO), and retinal vein occlusion (RVO) over time. The results show that the visual acuity and treatment patterns remained stable from 2015 to 2019 for patients with these eye diseases.
Article
Oncology
Ozkan Kocamis, Emine Temel, Gokcen Ozcan, Nazife Asikgarip, Kemal Ornek
Summary: This study evaluated the choroidal vascularity index (CVI) in patients with refractory diabetic macular oedema (DME) after a single dose of intravitreal dexamethasone implant. The results showed a significant decrease in CVI after treatment, indicating potential benefits of this treatment for improving macular oedema in patients.
PHOTODIAGNOSIS AND PHOTODYNAMIC THERAPY
(2022)
Review
Medicine, General & Internal
Mariantonia Ferrara, Alessandra Loda, Giulia Coco, Piergiacomo Grassi, Silvia Cestaro, Sara Rezzola, Vito Romano, Francesco Semeraro
Summary: Diabetic retinopathy (DR) is the most common microvascular complication of diabetes mellitus and the leading cause of acquired blindness in the working-age population. Clinical biomarkers play a crucial role in the early diagnosis of DR and the detection of prognostic factors, as symptoms may be absent in the early stages. Imaging techniques are fundamental tools for various aspects of DR management.
JOURNAL OF CLINICAL MEDICINE
(2023)
Article
Ophthalmology
Meng-Ju Tsai, Cheng-Kuo Cheng
Summary: The study found that non-perfused macula was significantly associated with both the development and poor restoration of EZ disruption. The duration of EZ disruption could be more predictive for improvement of vision over 12 months compared to baseline status.
CLINICAL AND EXPERIMENTAL OPTOMETRY
(2022)
Article
Ophthalmology
Sanjeeb Bhandari, David Squirrell, Vuong Nguyen, Nancy Wang, Jane M. Wells, Terence Tan, Rachel Barnes, Richard Barry, Daniel Barthelmes, Mark Gillies
Summary: In routine clinical practice, bevacizumab was shown to be an effective treatment for diabetic macular oedema (DMO) in unselected populations. Eyes with better vision tended to maintain their vision, while eyes with worse vision showed improvement over the observation period.
Article
Immunology
Ian J. C. MacCormick, Valentina Barrera, Nicholas A. Beare, Gabriela Czanner, Michael Potchen, Samuel Kampondeni, Robert S. Heyderman, Alister G. Craig, Malcolm E. Molyneux, Macpherson Mallewa, Valerie A. White, Dan Milner, Paul Hiscott, Terrie E. Taylor, Karl B. Seydel, Simon P. Harding
Summary: In cerebral malaria, retinal vascular leakage is associated with brain swelling and death. Retinal blood vessel rupture can cause cerebral hemorrhage and brain swelling, while vessel leak and barrier dysfunction are associated with neurological deficits.
JOURNAL OF INFECTIOUS DISEASES
(2022)
Article
Dermatology
M. J. Lavery, B. O'Brien, F. Jmor, V. Price, G. Guthrie, N. Khirwadkar, N. Beare, M. Wood
CLINICAL AND EXPERIMENTAL DERMATOLOGY
(2021)
Article
Ophthalmology
Lorna Leandro, Nicholas Beare, Kanchan Bhan, Philip I. Murray, Colm Andrews, Erika Damato, Alastair K. Denniston, Nitin Gupta, Periyasamy Kumar, Archana Pradeep, Fahd Quhill, Adam Ross, Amira Stylianides, Srilakshmi M. Sharma
Summary: The study found that 33.7% of uveitis patients in the UK were prescribed high-dose systemic corticosteroids over the past 12 months. 25% of these excessive prescriptions were deemed avoidable, with reasons such as long-term corticosteroid use without consideration of alternatives, prescribing errors, or miscommunication.
Correction
Ophthalmology
Asterios Diafas, Nima Ghadiri, Nick Beare, Savita Madhusudhan, Ian Pearce, Shi Zhuan Tan
Article
Ophthalmology
Eleftherios I. Agorogiannis, Deena Maleedy, Navid Hakim, David McDaid, Laura Silver, Savita Madhusudhan, Nicholas A. V. Beare
Article
Ophthalmology
Xiaoxuan Liu, Aditya U. Kale, Giovanni Ometto, Giovanni Montesano, Alice J. Sitch, Nicholas Capewell, Charlotte Radovanovic, Nicholas Bucknall, Nicholas A. V. Beare, David J. Moore, Pearse A. Keane, David P. Crabb, Alastair K. Denniston
Summary: The study demonstrates that optical coherence tomography (OCT) can reliably quantify vitreous haze (VH) and its measurement is associated with clinical grading of VH and visual acuity (VA). However, the accuracy of OCT measurements may be affected by media opacities.
TRANSLATIONAL VISION SCIENCE & TECHNOLOGY
(2022)
Review
Respiratory System
Onn Min Kon, Nicholas Beare, David Connell, Erika Damato, Thomas Gorsuch, Guy Hagan, Felicity Perrin, Harry Petrushkin, Jessica Potter, Charanjit Sethi, Miles Stanford
Summary: The BTS clinical statement on ocular tuberculosis in adults outlines the current understanding of disease pathogenesis, diagnosis, and management, while also acknowledging the lack of high-quality evidence and animal model data. Consensus points and best practices are provided to improve and standardize patient care.
BMJ OPEN RESPIRATORY RESEARCH
(2022)
Letter
Ophthalmology
Kyle J. Wilson, Nicholas A. V. Beare
Review
Ophthalmology
Nicholas A. V. Beare
Summary: Cerebral malaria (CM) is a common cause of death in African children, with an annual mortality of 400,000. Malarial retinopathy is a unique set of fundus signs that have diagnostic and prognostic value in CM. The assessment of malarial retinopathy is widely used in clinical care and research.
Article
Ophthalmology
Paul J. Steptoe, Ian Pearce, Nicholas A. V. Beare, Sreekanth Sreekantham, Bashar R. Mohammed, Robert J. Barry, Alastair K. Denniston, Philip I. Murray
Summary: This study evaluated the efficacy of treatment on acute posterior multifocal placoid pigment epitheliopathy (APMPPE) and relentless placoid chorioretinopathy (RPC). The results showed that natural history alone appears to be as effective as corticosteroid treatment, with less lesion development in the observed group.
OCULAR IMMUNOLOGY AND INFLAMMATION
(2023)
Letter
Parasitology
Jamie Burke, Neeraj Dhaun, Baljean Dhillon, Kyle J. Wilson, Nicholas A. V. Beare, Ian J. C. MacCormick
TRENDS IN PARASITOLOGY
(2023)
Review
Ophthalmology
Oliver Mase, Mustafa Qasem, Nicholas Beare
Summary: This study aimed to compare the effectiveness of adalimumab (ADA) and infliximab (IFX), two biological anti-tumour necrosis factor agents, in the management of autoimmune uveitis. The findings of six included studies suggested that ADA and IFX have similar effectiveness and safety profiles in the treatment of autoimmune uveitis. However, the available evidence is limited, of low quality, and at high risk of bias, indicating the need for large randomized controlled trials to provide more substantial evidence.
BMJ OPEN OPHTHALMOLOGY
(2023)
Correction
Ophthalmology
Kyle J. Wilson, Nicholas A. V. Beare
Article
Geriatrics & Gerontology
Jacqueline Ramke, Jennifer R. Evans, Esmael Habtamu, Nyawira Mwangi, Juan Carlos Silva, Bonnielin K. Swenor, Nathan Congdon, Hannah B. Faal, Allen Foster, David S. Friedman, Stephen Gichuhi, Jost B. Jonas, Peng T. Khaw, Fatima Kyari, Gudlavalleti V. S. Murthy, Ningli Wang, Tien Y. Wong, Richard Wormald, Mayinuer Yusufu, Hugh Taylor, Serge Resnikoff, Sheila K. West, Matthew J. Burton
Summary: Through the Grand Challenges in Global Eye Health exercise, key issues in improving eye health have been identified and specific challenges have been prioritised. This list can guide funders in investing in research and innovation in the field of eye health, and encourages collaboration among researchers, clinicians, and policy makers to address these challenges.
LANCET HEALTHY LONGEVITY
(2022)
Article
Public, Environmental & Occupational Health
Jacqueline Ramke, Jennifer R. Evans, Esmael Habtamu, Nyawira Mwangi, Juan Carlos Silva, Bonnielin K. Swenor, Nathan Congdon, Hannah B. Faal, Allen Foster, David S. Friedman, Stephen Gichuhi, Jost B. Jonas, Peng Khaw, Fatima Kyari, Gudlavalleti V. S. Murthy, Ningli Wang, Tien Y. Wong, Richard Wormald, Mayinuer Yusufu, Hugh Taylor, Serge Resnikoff, Sheila K. West, Matthew J. Burton
Summary: By conducting a prioritisation exercise, researchers identified key issues in global eye health and developed both global and regional priority lists, providing a roadmap for immediate action and collaboration to address specific challenges.
LANCET GLOBAL HEALTH
(2022)
